Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40612 (Exact name of registrant as specified in its charter) Non-accelerated filer ☒ Smaller reporting compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 26-4231384 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 303A College Road East, Princeton, NJ 08540 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Acquisition Strategy - As of March 31, 2025, the Company has acquired nine insurance agencies as part of its aggressive acquisition strategy[61] - The Company plans to acquire 80% of Spetner Associates for $16,050,000, which includes $6,500,000 in cash and the issuance of common stock and promissory notes[62] - The Company focuses on acquiring undervalued wholesale and retail insurance agencies in growing or underserved segments, including healthcare and Medicare[68] - The Company aims to expand its business through continued asset acquisitions and organic growth over the next 12 months[62] Financial Performance - Commission income for Q1 2025 was $4,236,220, a 4% increase from $4,082,438 in Q1 2024[77] - Total operating expenses decreased by 38% to $5,643,362 in Q1 2025 from $9,114,159 in Q1 2024[77] - Net loss improved to $(1,736,882) in Q1 2025, a 68% reduction from $(5,346,663) in Q1 2024[79] - AEBITDA for Q1 2025 was $145,407, compared to $(73,654) in Q1 2024, representing a significant turnaround[79] - Cash balance as of March 31, 2025, was approximately $1,812,000, with negative working capital of approximately $77,000[80] - Net cash provided by operating activities was $197,830 in Q1 2025, compared to net cash used of $(204,382) in Q1 2024[83] - Cash used in investing activities was approximately $14,944 in Q1 2025, down from $29,444 in Q1 2024[85] - Cash used in financing activities decreased to $169,073 in Q1 2025 from $392,100 in Q1 2024[86] - The company experienced a 15% increase in commission expenses, correlating with revenue growth[77] Operational Strategy - The 5MinuteInsure.com platform operates in 46 states and allows consumers to compare quotes from up to 30 insurance carriers, utilizing advanced AI and data mining techniques[62] - RELI Exchange has increased its agent roster by over 300% since its inception, providing a B2B InsurTech platform for agency partners[63] - The Company adopted a "OneFirm" strategy to enhance market presence and improve relationships with carriers, leading to better commission contracts[64] Market Challenges - The competitive landscape includes challenges from technology companies entering the insurance intermediary business and direct sales by insurance companies[65] - The company noted potential impacts of inflation on operating expenses, particularly in labor and facility leases[81] Stock and Shareholder Information - The Company effectuated a 1-for-17 reverse stock split on July 1, 2024, resulting in a rounding addition of approximately 110,350 shares valued at par, totaling $9,490[72] Key Financial Metrics - Adjusted EBITDA (AEBITDA) is a key financial performance metric used by the Company to evaluate operational performance across reporting periods[73]

Exhibit 99.1 Grove Announces First Quarter 2025 Financial Results SAN FRANCISCO, CA — May 14, 2025 — Grove Collaborative Holdings, Inc. (NYSE: GROV) ("Grove" or "the Company"), the world's first plastic neutral retailer, a leading sustainable consumer products company, certified B Corporation, and Public Benefit Corporation, today reported financial results for its fiscal first quarter ended March 31, 2025. Key Financial Highlights: "We are not satisfied with our first quarter performance and recognize that ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-32501 REED'S, INC. (Exact name of registrant as specified in its charter) (State of incorporation) Delaware 35-2177773 (I.R.S. Employer Identificati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State ...

Financial Performance - Net loss for Q1 2025 was $37.0 million, or $0.86 loss per share, compared to a net loss of $21.6 million, or $0.64 loss per share in Q1 2024[11]. - Non-GAAP adjusted net loss for Q1 2025 was $34.7 million, or $0.81 loss per share, compared to $19.9 million, or $0.59 loss per share in Q1 2024[11][23]. - GAAP net loss for Q1 2025 was $36.997 million, compared to a loss of $21.612 million in Q1 2024, representing a 71.2% increase in losses year-over-year[25]. - Non-GAAP adjusted net loss for Q1 2025 was $34.699 million, up from $19.904 million in Q1 2024, indicating a 74.5% increase in adjusted losses[25]. - GAAP net loss per share for Q1 2025 was $0.86, compared to $0.64 per share in Q1 2024, reflecting a 34.4% increase in loss per share[25]. - Non-GAAP adjusted net loss per share for Q1 2025 was $0.81, compared to $0.59 per share in Q1 2024, showing a 37.3% increase in adjusted loss per share[25]. Operating Expenses - Total operating expenses for Q1 2025 were $36.1 million, up from $22.5 million in Q1 2024, representing a 60% increase[8]. - Research and development expenses increased to $32.2 million in Q1 2025 from $20.6 million in Q1 2024, a rise of approximately 56%[9]. - Net cash used in operating activities for Q1 2025 was $35.9 million, compared to $17.1 million in Q1 2024[13]. Assets and Cash Position - Cash, cash equivalents, and investments totaled approximately $206 million as of March 31, 2025, expected to fund clinical development through 2026[5][13]. - Total current assets decreased to $217.6 million as of March 31, 2025, from $244.6 million at the end of 2024[19]. Clinical Trials - The topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 trial is anticipated in Q3 2025, with the primary completion date projected for June 2025[5][6]. - Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 trial, with topline data expected in Q4 2025[5][6]. - The VIKTORIA-2 Phase 3 trial is on track to dose its first patient in Q2 2025[5][6]. Shareholder Information - Weighted average common shares outstanding increased to 43,052,757 in Q1 2025 from 33,612,054 in Q1 2024, a growth of 28.0%[25].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______, 20___, to _____, 20___. Commission File Number 001-42538 JFB CONSTRUCTION HOLDINGS (Former name, former address and former fiscal year, if changed since last report) ...

Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year DUBLIN, IRELAND - (May 14, 2025) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic revenue growth from continuin ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 Scilex Holding Company For the transition period from to Commission File Number 001-39852 (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incor ...